Skip to main content
Caplight Logo









Invitris

Invitris

Private
MunichHealthcare & Life Scienceshttps://www.invitris.com/

Last Round

Grant

Feb 17, 2025

Est. Valuation

$1.79M

Total Funding Raised

$3.34M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Invitris is a biotechnology company that develops a cell-free protein expression platform called Phactory™ to manufacture therapeutic proteins, including bacteriophages, to combat antibiotic-resistant infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

cell-free protein synthesissynthetic biologyprotein engineeringbacteriophage developmentantimicrobial resistancephage therapydrug discovery platformbiotech infrastructurehigh-throughput screeningcomputational protein designendolysinprotein expressionlab-on-a-chipbiomanufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invitris Comparables

Compare Invitris with similar companies based on industry and business-model similarity.

Invitris comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LenioBio
83%
Tierra Biosciences
79%
Sutro Biopharma Inc
74%

Invitris Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 17, 2025
AcceleratorDec 19, 2024
GrantMay 9, 2023
AcceleratorMar 10, 2023
GrantJan 27, 2022

Key People

Founding team and executive leadership

Patrick Grossmann

CEO Co-Founder

Founding Team

Invitris Investors

Notable investors and investment history

Invitris investors
InvestorRounds
European Innovation Council FundAccelerator, Grant
INCATEGrant
Y CombinatorAccelerator
another.vcAccelerator
10x FoundersAccelerator
Mergus VenturesAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 928% MoM, from 157 to 1.6K.

  • May 16, 2026

    Monthly visitors increased 1403% from 61 to 917.

Invitris Filings

Explore SEC and related filing metadata, where available.

Invitris filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Invitris's valuation, stock price, and market status.

Is Invitris a public or private company?

Invitris is a private company.

What is the current stock price of Invitris?

Invitris is a private company with no public stock price. No recent secondary market data is available.

How much is Invitris worth (valuation)?

Valuation information for Invitris is not publicly available.

Can I buy Invitris stock?

Invitris shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Invitris's last funding round?

Invitris's most recent funding round was Grant on February 17, 2025.

Who are the main investors in Invitris?

Key investors in Invitris include European Innovation Council, INCATE.

Will Invitris IPO soon?

No public IPO plans have been announced for Invitris.

How can I track Invitris secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Invitris's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMunich
Employee Range19
Year Founded2018
Last FundingFeb 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?